FMP
NASDAQ
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
10.78 USD
-0.32 (-2.97%)
Valuation Date:
May 3, 2024 4:00 PM
Share Price on Valuation Date
$10.78
Stock Beta
2.126
Shares Outstanding
47550900